百诚医药(301096.SZ)：创新药BIOS-0623-Z4片获得临床试验批准

Core Viewpoint - 百诚医药's innovative drug BIOS-0623-Z4 has received clinical trial approval from the National Medical Products Administration (NMPA) in China, marking a significant milestone for the company in the oncology pain management sector [1] Company Summary - 百诚医药 has developed BIOS-0623-Z4, a non-opioid drug targeting adult cancer pain treatment, which currently has no other drugs with the same target and indication available in the market [1] - The drug is classified as a Class 1 chemical drug and is categorized as an innovative drug that has not been marketed domestically or internationally [1]